Whether or not you set new year’s resolutions in a formal way, it’s good to have support for whatever you intend to do.

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Check out this year's top 5 pieces of sleep coverage that cover topics surveying the benefits of supplements, novel ...

Wall Street saw gains as the S&P 500 rose 0.7% and the Nasdaq climbed 1%, driven by tech and communications stocks. Despite weak consumer confidence data, positive economic reports and interest rate ...

Stocks closed higher on Wall Street at the start of a holiday-shortened week. The S&P 500 rose 0.7% Monday. Several big ...

Honda and Nissan merger talks stir Wall Street, as tech stocks like Nvidia and Broadcom provide market support. Meanwhile, ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” Dr. Sally Seymour ...

ABC News' Dr. Darien Sutton breaks down the FDA’s approval of the popular weight loss medication for the treatment of ...

Following his impressive fourth-place finish in the Mouttet Mile on December 7, Donovan Hutchinson’s Further and Beyond is ...

Following the historic qualification of Jamaica’s men’s and women’s rugby sevens sides for next year’s Junior Pan American ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved to ...